EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation

Şeyma Özden, Fatma Merve Tepetam, Yunus Bozkurt, Fatma Terzioğlu Şahin, Aysun Aynacı, Hasan Furkan Avcı, Mazlum Dursun, Mustafa Asım Demirkol, Nihal Yıldırım

International Archives of Allergy and Immunology · 2026

DOI: 10.1159/000550316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2026. Verfasst von Şeyma Özden und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Allergy, University of Health Sciences, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, …. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents, Eosinophils. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Benralizumab, an anti-IL-5 receptor monoclonal antibody, induces near-complete eosinophil depletion and has demonstrated significant clinical benefits in severe eosinophilic asthma (SEA). Real-world data remain essential for evaluating its effectiveness outside controlled trial settings. The aim of the study was to assess the clinical, laboratory, and functional outcomes of benralizumab over 32 weeks in a real-life cohort of SEA patients in Türkiye, following its recent national approval.

Methods

This retrospective study included biologic-naïve adults with SEA who initiated benralizumab between November 2023 and February 2025 and completed at least six consecutive doses. Peripheral blood eosinophil count (PBEC), clinically significant exacerbations (CSEs), Asthma Control Test (ACT) scores, and spirometric parameters were evaluated at baseline and week 32. Patients were classified as responders (ACT ≥20 and no CSE) or nonresponders.

Results

Twenty-four patients (66.7% female; mean age 50.9 ± 13.1 years) were included. Median PBEC decreased from 800 (230–2,200) to 0 (0–100) cells/µL (p < 0.001). Median annual CSE frequency declined by 67% (p < 0.001). ACT scores improved from 9 (5–24) to 22 (9–25) (p < 0.001). Mean forced expiratory volume in 1 s (FEV1) increased from 1,719 ± 768 mL to 2,165 ± 831 mL (p < 0.001), while forced vital capacity (FVC) showed significant improvement. Forced expiratory flow between 25% and 75% of the FVC (FEF25–75) exhibited a nonsignificant trend toward increase. Sixteen patients (66.7%) were classified as responders. Responders had higher baseline PBEC, FEV1, and FEF25–75 values. Benralizumab was well tolerated, with only two mild adverse events observed.

Conclusion

Benralizumab provided substantial improvements in eosinophilic inflammation, exacerbation frequency, symptom control, and lung function over 32 weeks in a real-life SEA cohort. These findings support benralizumab as an effective and well-tolerated therapeutic option in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsEosinophilsHumansMaleFemaleMiddle AgedAdultTreatment OutcomeRetrospective StudiesSeverity of Illness IndexAgedLeukocyte Count

Stichwörter der Autor:innen

AsthmaEosinophilic inflammationPolyposisSevere asthmaSpirometry

Substanzen

benralizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Immunology and Allergy, University of Health Sciences, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey, seymaglhn@hotmail.com.
  • Department of Immunology and Allergy, University of Health Sciences, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.

Zitieren

APA

Özden, Ş., Tepetam, F. M., Bozkurt, Y., Terzioğlu Şahin, F., Aynacı, A., Avcı, H. F., Dursun, M., Demirkol, M. A., & Yıldırım, N. (2026). Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation. International Archives of Allergy and Immunology. https://doi.org/10.1159/000550316

Vancouver

Özden Ş, Tepetam FM, Bozkurt Y, Terzioğlu Şahin F, Aynacı A, Avcı HF, et al. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation. International Archives of Allergy and Immunology. 2026. doi:10.1159/000550316

BibTeX
@article{zden2026,
  author = {Özden, Şeyma and Tepetam, Fatma Merve and Bozkurt, Yunus and Terzioğlu Şahin, Fatma and Aynacı, Aysun and Avcı, Hasan Furkan and Dursun, Mazlum and Demirkol, Mustafa Asım and Yıldırım, Nihal},
  title = {Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation},
  journal = {International Archives of Allergy and Immunology},
  year = {2026},
  doi = {10.1159/000550316}
}
Kostenlos starten →